Avalo Therapeutics (AVTX)
NASDAQ:AVTX
AVTX Stock Chart & Stats
$13.34
-$0.55(-7.32%)
At close: 4:00 PM EST
$13.34
-$0.55(-7.32%)
Day’s Range― - ―
52-Week Range$3.39 - $20.72
Previous CloseN/A
Volume10.82K
Average Volume (3M)826.05K
Market Cap
$311.29M
Enterprise Value$137.23M
Total Cash (Recent Filing)$98.34M
Total Debt (Recent Filing)$2.43M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Apr 30, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding22,788,452
10 Day Avg. Volume862,934
30 Day Avg. Volume826,051
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.93
Price to Sales (P/S)4125.96
P/FCF Ratio-4.73
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue2.33K
Enterprise Value/Gross Profit3.19K
Enterprise Value/Ebitda-1.63
Forecast
1Y Price Target
$42.44Price Target Upside218.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data TransparencyManagement plans to disclose the full intent-to-treat dataset including demographics, safety, the primary endpoint, and a meaningful portion of secondary endpoints, reducing investor uncertainty about trial results.
Differentiated Mechanism Of ActionSelective targeting of IL-1 beta with higher binding affinity and improved subcutaneous availability positions abdakibart to offer differentiated efficacy and better tolerability versus dual-target or IL-1 alpha agents.
Dosing And Commercial PositioningA longer half-life and an intended monthly dosing approach could provide less frequent injections that align with patient preference and support persistence advantages in the hidradenitis suppurativa market.
Bears Say
Competitive Benchmark PressureStrong commercial performance and established efficacy of leading IL-17 therapy create a high benchmark, so failing to demonstrate clear clinical or dosing advantages would hinder market uptake.
Placebo Response RiskA prior trial of a related agent failed to meet significance because of an unusually high placebo response, highlighting the risk that variable placebo effects could obscure true drug benefit.
Avalo Therapeutics News
AVTX FAQ
What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was $3.39 and its highest was $20.72 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Avalo Therapeutics’s market cap is $311.29M.
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 16 days.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Mar 23, 2026. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$1.458 by $0.708.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -1.18.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 22,788,452 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -$0.75 in its last earnings report, beating expectations of -$1.458. Following the earnings report the stock price went up 0.596%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Currently, no hedge funds are holding shares in AVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avalo Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.44 (218.14% Upside)
$42.44 (218.14% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 52.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $411.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.51%
12-Months-Change
Fundamentals
Return on Equity
-77.91%
Trailing 12-Months
Asset Growth
-21.91%
Trailing 12-Months
Company Description
Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX Stock 12 Month Forecast
Average Price Target
$42.44
▲(218.14% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Fractyl Health, Inc.
―